ArticleJournal of the American Heart Association2026
CircRNA-TMEM71 Inhibits Human Aortic Smooth Muscle Cell Ferroptosis and Prevents Aortic Dissection Formation Through IGF2BP3-Mediated Stability of FSP1.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAortic dissection (AD) is a severe cardiovascular disease with high mortality and limited treatment options. Previous studies have shown that circular RNA and ferroptosis play significant roles in various cardiovascular diseases, regulating disease progression. However, there is little research on how circular RNA regulates ferroptosis in vascular smooth muscle cells during AD progression, and the specific molecular mechanisms remain a mystery. METHODS AND
resultsIn this study, we found that circTMEM71 is downregulated in AD and angiotensin II-induced human aortic smooth muscle cells and inhibits ferroptosis. Mechanistically, circTMEM71 can bind to IGF2BP3 (insulin-like growth factor II mRNA-binding protein 3) and inhibit its degradation via the ubiquitin-mediated proteasome pathway. Additionally, IGF2BP3 can bind to FSP1 (ferroptosis suppressor protein 1) mRNA, enhancing its stability and thus suppressing cellular ferroptosis. Finally, we also confirmed that circTMEM71 can alleviate symptoms of AD in Sprague-Dawley rats through in vivo experiments, including histopathologic changes and ferroptosis.
conclusionsIn summary, our study suggested that circTMEM71 is a potential therapeutic target for AD and highlights its role in inhibiting ferroptosis in vascular smooth muscle cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.